Form 4: Enliven Therapeutics' Chief Scientific Officer Sells Shares

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 3,099 shares of common stock on July 31, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 31, 2024, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, sold 3,099 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• The shares were sold at a weighted average price of $27.5571, with individual transactions ranging from $27.50 to $27.655.
• Following the transaction, Lyssikatos directly owns no shares but indirectly owns 1,089,936 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine transaction under a pre-planned trading arrangement. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

Insider sales are a common occurrence, and the use of a pre-arranged Rule 10b5-1 trading plan suggests the sale was planned and not based on any specific non-public information.

Stakeholder Impact

• The sale of shares by a high-ranking officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates